Intervention

Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]

ClinicalTrials.gov intervention label

Clinical trials3

Recruiting0

Common conditions4

Lead sponsors shown3

Clinical trials

3 shown

Semaglutide for the Prevention Of Post-Transplant Diabetes MellitusNCT06913023 · 2026-09-05

NOT_YET_RECRUITING

Semaglutide 2.4mg for Low Responders After Bariatric SurgeryNCT06287307 · 2024-05-01

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term EffectsNCT05548647 · 2022-07-26

Common conditions

Obesity2 Kidney Transplant Recipient1 Obesity, Morbid1 Weight Gain1

Leading sponsors

University Health Network, Toronto1 University of Pennsylvania1 Zuyderland Medisch Centrum1

Trial status mix

COMPLETED1

NOT_YET_RECRUITING1

UNKNOWN1

Phase mix

PHASE42

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.